An endostatin-derived peptide orally exerts anti-fibrotic activity in a murine pulmonary fibrosis model
- 1 October 2015
- journal article
- Published by Elsevier in International Immunopharmacology
- Vol. 28 (2) , 1102-1105
Abstract
No abstract availableKeywords
Funding Information
- iBio Inc.
- NIH
This publication has 15 references indexed in Scilit:
- Toward Oral Delivery of Biopharmaceuticals: An Assessment of the Gastrointestinal Stability of 17 Peptide DrugsMolecular Pharmaceutics, 2015
- Pirfenidone: A Review of Its Use in Idiopathic Pulmonary FibrosisDrugs, 2015
- Cyclic Penta- and Hexaleucine Peptides without N-Methylation Are Orally AbsorbedACS Medicinal Chemistry Letters, 2014
- Efficacy and Safety of Nintedanib in Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2014
- A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2014
- A Peptide Derived from Endostatin Ameliorates Organ FibrosisScience Translational Medicine, 2012
- Systemic sclerosis refractory disease: From the skin to the heartAutoimmunity Reviews, 2011
- Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in miceJournal of Clinical Investigation, 2009
- Induction of immune tolerance to human type I collagen in patients with systemic sclerosis by oral administration of bovine type I collagenArthritis & Rheumatism, 2000
- Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor GrowthCell, 1997